Price
60
-0.5%52W Range
Market Cap
₹176.74 Cr
Traded: ₹0.11 Cr (0.06%) 0.0x
Free Float: ₹61.47 Cr (0.18% of FF traded)
Volume · 60D trend
18.99 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | -- | -9.0% | -2.0% | -- | -- | Accelerating |
| Return | -2.0% | -12.0% | -14.0% | -56.0% | -- | Decelerating |
| Profit | -- | +27.0% | +47.0% | -- | +551.0% | Accelerating |
| Sales | -- | +2.0% | +11.0% | -- | -8.0% | Stable |
Quarterly Results
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 23 | 20 | 17 | 23 | 26 | 23 | 21 | 21 | 18 | 18 | 22 | 24 | 16 | 13 | 15 | 18 |
| Expenses | 24 | 20 | 16 | 21 | 22 | 25 | 22 | 24 | 20 | 27 | 25 | 25 | 20 | 16 | 24 | 27 |
| Operating Profit | -1 | 1 | 1 | 3 | 3 | -1 | -2 | -3 | -2 | -10 | -3 | -1 | -4 | -4 | -9 | -9 |
| OPM % | -5.8% | 3.4% | 4.4% | 10.8% | 12.3% | -5.4% | -7.3% | -16.4% | -10.7% | -53.8% | -15.5% | -4.5% | -24.9% | -29.3% | -55.9% | -51.0% |
| Other Income | 0 | 1 | 5 | 6 | 7 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| Profit Before Tax | -2 | 2 | 6 | 8 | 10 | -1 | -2 | -4 | -2 | -10 | -4 | -2 | -4 | -4 | -11 | -12 |
| Tax % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 13.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.8% | 0.0% | 0.0% | 0.0% | -15.2% | -32.8% |
| Net Profit | -2 | 2 | 6 | 8 | 10 | -1 | -2 | -4 | -2 | -10 | -4 | -2 | -4 | -4 | -9 | -8 |
| Exceptional Items | -- | -- | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Rs) | -0.6 | 0.5 | 1.9 | 2.7 | 3.3 | -0.5 | -0.8 | -1.5 | -0.9 | -3.7 | -1.5 | -0.6 | -1.7 | -1.6 | -1.9 | -1.8 |
| Sales Growth (YoY) | -10.0% | -13.3% | -19.3% | 12.8% | 42.3% | 31.6% | -5.7% | -14.5% | 14.2% | 40.5% | 42.2% | 34.5% | -- | -- | -- | -- |
| Sales Growth (QoQ) | 13.6% | 22.0% | -29.3% | -8.1% | 9.4% | 13.7% | -1.3% | 15.9% | 1.2% | -18.5% | -10.6% | 54.9% | 24.5% | -17.6% | -15.4% | -- |
| OP Growth (YoY) | -142.8% | 154.0% | 148.7% | 173.9% | 263.0% | 86.8% | 55.5% | -210.0% | 50.9% | -157.6% | 60.6% | 88.1% | -- | -- | -- | -- |
| OP Growth (QoQ) | -297.1% | -6.8% | -71.0% | -19.5% | 348.4% | 16.0% | 56.0% | -77.6% | 79.9% | -182.8% | -206.4% | 71.9% | -5.7% | 56.7% | 7.3% | -- |
| Profit Growth (YoY) | -119.0% | 204.0% | 358.0% | 302.0% | 498.0% | 85.0% | 45.0% | -141.0% | 46.0% | -124.0% | 26.0% | 65.0% | 35.0% | -19.0% | 21.0% | 3.0% |
| EPS Growth (YoY) | -118.8% | 204.0% | 330.9% | 279.5% | 453.3% | 86.3% | 45.3% | -143.6% | 46.2% | -123.2% | 22.9% | 65.4% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -217.3% | -72.2% | -31.0% | -16.6% | 750.0% | 38.3% | 46.4% | -64.1% | 74.9% | -147.3% | -138.7% | 63.7% | -4.3% | 14.6% | -7.3% | -- |
| OP Margin | -5.8% | 3.4% | 4.4% | 10.8% | 12.3% | -5.4% | -7.3% | -16.4% | -10.7% | -53.8% | -15.5% | -4.5% | -24.9% | -29.3% | -55.9% | -51.0% |
| Net Margin | -7.8% | 7.5% | 33.2% | 34.0% | 37.5% | -6.3% | -10.4% | -19.1% | -13.4% | -54.2% | -17.8% | -6.7% | -28.5% | -34.0% | -62.0% | -43.5% |
| Material Cost % | 55.0% | 61.0% | 54.0% | 58.0% | 62.0% | 68.0% | 62.0% | 63.0% | 69.0% | 72.0% | 71.0% | 72.0% | 70.0% | 65.0% | 75.0% | 82.0% |
| Employee Cost % | 18.0% | 19.0% | 22.0% | 17.0% | 14.0% | 14.0% | 16.0% | 15.0% | 17.0% | 13.0% | 13.0% | 11.0% | 18.0% | 18.0% | 27.0% | 29.0% |
| P/S | 2.12 | 2.25 | 2.16 | 2.13 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 13.36 | 7.86 | 8.91 | 14.43 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 1.45 | 1.58 | 1.67 | 1.72 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Please find enclosed herewith Addendum to the Notice of 24th Annual General Meeting.
Please find attached addendum to the notice of 24th Annual General Meeting.
Addendum to the Notice of 24th Annual General Meeting of the Company.
Intimation of Record date, E-Voting dates and Book Closure date.
Newspaper publication dated 14th August 2026 of Unaudited Financial Results for the quarter ended 30th June 2026.
Financial Results for quarter ended June 30,2026.
Outcome of Board Meeting held on Thursday, 13th August, 2026
Newspaper publication regarding 24th AGM of the Company to be held on 3rd September 2026.
Letter to the Shareholders-Annual Report for the FY 2025-26
Notice of 24th Annual General Meeting of the Company to be held on 3rd September 2026 through VC/OAVM.
Pursuant to Regulation 34 read with Regulation 30 of SEBI Listing Regulations, we are enclosing herewith the following: 1. Notice of the AGM.2. Annual Report for the Financial Year 2025-26.
Newspaper Advertisement - Intimation of 24th Annual General Meeting of the Company through VC/OAVM.
Brooks Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve and take on record the ....
Appointment of Mr. Rajesh Mahajan as President - Trading.
We hereby inform that, further to the disclosure made by the Company on 19th June 2026 regarding proposed sale of a portion of its shareholding in Brooks Steriscience Limited.
Certificate under Regulation 74(5) of SEBI (DP) Regulation, 2018 for quarter ended 30th June 2026.
Intimation of Incorporation of Wholly Owned Subsidiary.
Intimation of Closure of Trading Window.
With reference to corporate announcement titled "Partial Sale of Equity Shares held in Brooks Steriscience Limited" submitted by the Company on 19th June 2026, we wish to inform you that ....
We hereby inform that the Company at its board meeting held today i.e 19th June 2026 has approved sale of 51,220 equity shares held by the Company in Brooks Steriscience Limited to Steriscience ....
Newspaper Publication dated 30th May 2026 of Audited Financial Results for the quarter and year ended 31st March 2026.
Annual Secretarial Compliance Report of the financial year ended 31st March 2026
Appointment of Chief Executive Officer.
Outcome of Board Meeting held on Held On Friday, 29th May 2026.
Outcome of the Board Meeting held on Friday, 29th May 2026
Brooks Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve and take on record the ....
Update on Scheme of Arrangement involving Brooks Steriscience Limited ("BSL"), a Joint Venture / Associate of the Company.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Certificate under Regulation 74(5) of SEBI(DP) Regulation, 2018 for quarter ended 31st March 2026.
Reply to clarification sought vide email dated 1st April 2026 with reference to Price Movement.
The Exchange has sought clarification from Brooks Laboratories Ltd on April 1, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
Intimation of Closure of Trading Window.
Newspaper Publication regarding the Special Window open for re-lodgement of transfer deed.
We refer to our intimation dated September 26, 2025 regarding update on Scheme of Arrangement involving Brooks Steriscience Limited ("BSL"), a Joint Venture/Associate of the Company.
Newspaper Publication dated 7th February 2026 of the Unaudited Financial Results of the Company for the quarter and nine months ended 31st December 2025.
Outcome of the Board Meeting held on Friday, 6th February 2026.
Outcome of Board Meeting held on Friday, 6th February 2026.
This is to inform you that the Company has received ITAT orders the details is provided in Annexure A.
Brooks Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2026 ,inter alia, to consider and approve and take on record the ....
Compliance Certificate under Regulation 74(5) of SEBI(Depositories and Participants) Regulations, 2018 for the quarter ended 31st December 2025.
Closure of Trading Window effective from Thursday, 1st January 2026 until 48 hours after the declaration of the Financial Results of the Company for the quarter and nine months ended 31st ....
Newspaper Publication dated 15th November 2025 of the Unaudited Financial Results of the Company for the quarter and half year ended 30th September 2025.
Outcome of the Board Meeting held on Friday, 14th November 2025.
Approved Results for quarter and half year ended 30th September 2025 at Board Meeting held on Friday 14th November, 2025
Intimation of Credit Rating under Regulation 30 of SEBI(LODR) 2015.
Brooks Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 ,inter alia, to consider and approve and take on record the ....
Change in Senior Management Personnel.
Compliance Certificate under Regulation 74(5) of SEBI(Depositories and Participants) Regulations 2018 for the quarter ended September 30, 2025.
Scrutinizer Report along with voting results for the AGM held on September 26, 2025
Closure of Trading window effective from Wednesday, 1st October 2025 until 48 hours after the declaration of Unaudited Financial Results of the Company for the quarter and half year ended ....
Annual Reports
16Held by Mutual Funds
1 schemes hold brooks · sorted by weight